abrdn plc Increases Holdings in Moderna, Inc. (NASDAQ:MRNA)

abrdn plc boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 28.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 315,912 shares of the company's stock after acquiring an additional 69,360 shares during the period. abrdn plc owned 0.08% of Moderna worth $12,842,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB increased its stake in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after purchasing an additional 389 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after purchasing an additional 388 shares during the last quarter. EMC Capital Management increased its stake in shares of Moderna by 311.2% in the 4th quarter. EMC Capital Management now owns 1,250 shares of the company's stock valued at $52,000 after purchasing an additional 946 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Finally, Rakuten Securities Inc. increased its stake in shares of Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock valued at $63,000 after purchasing an additional 778 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Morgan Stanley decreased their price target on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Wednesday, January 15th. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and cut their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Leerink Partners cut their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Piper Sandler reissued an "overweight" rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Finally, Wolfe Research assumed coverage on Moderna in a report on Friday, November 15th. They set an "underperform" rating and a $40.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $66.89.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last 90 days. Insiders own 15.20% of the company's stock.

Moderna Stock Down 2.9 %

Shares of NASDAQ:MRNA traded down $0.94 during mid-day trading on Tuesday, hitting $30.93. 10,072,079 shares of the company traded hands, compared to its average volume of 12,494,977. The stock has a market cap of $11.90 billion, a P/E ratio of -5.31 and a beta of 1.59. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12-month low of $30.70 and a 12-month high of $170.47. The stock has a 50-day moving average price of $39.77 and a two-hundred day moving average price of $56.76.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.